USFDA24 Apr 2026, 10:31 pm
Rubicon Research Canada R&D facility clears USFDA inspection
AI Summary
Rubicon Research Ltd announced that its R&D facility in Concord, Ontario, Canada, underwent an unannounced USFDA inspection from April 20 to April 24, 2026. The inspection concluded successfully with no Form-483 observations issued, indicating the facility's adherence to regulatory standards. The company reiterated its commitment to maintaining high standards of compliance and quality. This positive outcome is significant for its operations in the regulated pharmaceutical market.
Key Highlights
- USFDA inspected Rubicon Research's Canada R&D facility.
- Inspection occurred from April 20 to April 24, 2026.
- No Form-483 observations were issued by USFDA.
- Outcome reflects strong compliance and quality standards.